Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A blood-based marker of mitochondrial DNA damage in Parkinson’s disease

30 Aug 2023

Abstract excerpt

Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, and neuroprotective or disease-modifying interventions remain elusive. High-throughput markers aimed at stratifying patients on the basis of shared etiology are required to ensure the success of disease-modifying therapies in clinical trials. Mitochondrial dysfunction plays a prominent role in the pathogenesis of PD. Previously, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Lysosomal Storage Disorders Research
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37647388
DOI: 10.1126/scitranslmed.abo1557

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A blood-based marker of mitochondrial DNA damage in Parkinson’s diseasePMID 37647388Read ↗

A mitochondrial blood-based patient stratification candidate biomarker for Parkinson’s diseaseSemantic proximity Read ↗

Damage in Mitochondrial DNA Associated with Parkinson's DiseaseSemantic proximity Read ↗

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.Semantic proximity Read ↗

Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease.Semantic proximity Read ↗

Lewy body pathology is associated with mitochondrial DNA damage in Parkinson's diseaseSemantic proximity Read ↗

Mitochondrial DNA Deletions Discriminate Affected from Unaffected LRRK2 Mutation CarriersSemantic proximity Read ↗

Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease.Semantic proximity Read ↗

Mitochondrial DNA in Parkinson's disease.Semantic proximity Read ↗

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.Semantic proximity Read ↗

Reduced mitochondrial DNA copy number is a biomarker of Parkinson's diseaseSemantic proximity Read ↗

Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatmentSemantic proximity Read ↗

Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early‐stage Parkinson's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.